NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 3 Next »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Pihl, Todd (NIH/NCI) [C]

X
Unknown User (leblancak)
X

Otridge, John (NIH/NCI) [C]

X
Kim, Erika (NIH/NCI) [E]
X

Sommers, Connie (NIH/NCI) [E]

X
Debbie KnappX
Toby HechtX

Unknown User (parchmentr)



Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

Box Folder

https://nih.box.com/s/5wmrgl85z6fxpo3ldhanxzmmqq3ekfy7

Relevant Links for Today's Meeting

  1. Candidate Publication List
  2. Submission Folder for 1st Candidate Publication
  3. Submission Folder for PanCancer Study
  4. Data Transfer Agreement
  5. Data Use Guidelines

Outstanding Action Items


Discussion items

ItemWhoTalking Points
Steering Committee Meeting UpdatesUnknown User (parchmentr)
ICDC Next Phase

Unknown User (hechtt)

  • Next steps for soliciting a small group of comparative oncology researchers who are ICDC users
  • Recruitment results from PRECINCT SC meeting (Dec. 10th)
DGAB Updates

Kuffel, Gina (NIH/NCI) [C]

  • Data Transfer Agreement (DTA) has been finalized and is ready for use
    • Folder containing any artifacts related to the DTA can be found here
  • UBC02 - Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma Are Associated With Tumor Immune Signatures and Dog Breed - To be released to production next week, adds 122 files (349.5 GB)
  • Data ingestion PanCancer study to begin soon
    • Folder containing all submission artifacts for this study can be found here
  • Communications with authors of first candidate publication test case from Candidate Publication List
    • Data Submission Request was completed on their behalf
    • Email was sent by Warren Kibbe on behalf of DGAB on 11/24/21
    • Acknowledgment email sent by Gina 12/2/21
    • Follow-up email sent by by Gina 1/6/22
    • Folder containing all submission artifacts for this test case can be found here
Data Use Guidelines

Kuffel, Gina (NIH/NCI) [C] 

  • Review by Jason Cristofaro has been completed 
  • Link to draft document can be found here
User Research for ICDC by the Office of Communications and Public Liaison (OCPL)Kuffel, Gina (NIH/NCI) [C] 
  • Collecting use cases to test during the remote usability sessions with participants

  • To start off the test, the researcher will put the participant in a hypothetical scenario. From there, participants will be asked to use the resources on the portal to meet a goal.  For example, PDC's first scenario was this: 

    “You are conducting research for a study on Lung Cancer. For this study, you want to better understand which peptides may drive subtypes of the cancer. Using this site, find data sets on Lung Adenocarcinoma that will help you with your research. The data set(s) should include:  

    • Solid tissue 
    • Peptide spectral matches 
    • Gene p53  
  • Recruitment is critical- these will be folks targeted for user interviews
    • DGAB members
    • PRECINCT members
    • Pharmacodynamics group
    • Other groups, channels, or individuals?
ICDC Site Updates

Kuffel, Gina (NIH/NCI) [C]

  • Successful production release on December 15th
  • Data dictionary demo if others are interested

Minutes (Not Verbatim)


Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Previous Meeting Minutes (Not Verbatim)

EK - Collected use cases in 2019 before any data was in ICDC. Around 8 use cases were documented. Many of the responses included high-level, overarching concepts. To uncover the real scientific use cases we nee do talk with PostDcos and Grad Students.

TH- Comparative Oncology community will be interested in specific questions.

EK- NCPI has a team comprised of NHLBI, NCI, Common Fund, and NHGRI to provide use cases of interoperability across the platforms and cloud resources. We are exploring congenital cancer in Gliomas, we might be able to add canine glioma data to identify any correlations that may exist. Use cases are in the works. We solicited researchers to get the scientific use cases.

TH- Longitudinal studies can be very useful in dogs. We can use that data to draw comparisons in humans. We will probably give some funding to the Dog Aging Study that may be matched by the Dog Aging Institute. They have ~30k dogs they are following, healthy dogs, many develop cancer. They are willing to sequence if they had the funding.

JO- Valuable just to have healthy, normal dogs as well. Could they be a source for deposit into ICDC?

TH- Reference standards are prolific at this point. There is a new canine reference German Shepherd 1.0 named Mischka.

Action items

  • No labels